The Memorial Sloan Kettering Cancer Center (MSK) and Philips will exploit the latter’s IntelliSpace Genomics platform through their research collaboration to develop new genome analysis methods and informatics approaches for diagnosing pancreatic cancer and aiding personalized therapeutics. The collaboration will employ large-scale next-generation sequencing to generate new insights into the drivers of pancreatic cancer at the single-cell level, with the goal of enabling more precise diagnosis so that patients can be prescribed optimum treatments that target the cause of their disease. 

Philips' IntelliSpace Genomics platform has been developed to support the implementation and scaling of informatics-heavy precision medicine research. “Collaborating with MSK and its experts will allow us to take a unique approach to diagnosing and treating this devastating disease,” commented Henk van Houten, Ph.D., CTO at Philips. “Leveraging the advanced capabilities of the Philips IntelliSpace Genomics solution we can gain new insights into the origin, development, and optimal treatment of pancreatic cancer and share these insights broadly with care providers to help improve outcomes for patients. Our ultimate goal is to translate these findings into more precise diagnostics and therapeutics to battle this devastating disease.”

Philips and MSK have previously established a research collaboration in the field of radiation oncology. Just yesterday, MSK and Mabvax Therapeutics signed a research agreement to develop chimeric antigen receptor (CAR) T-cell immunotherapies for pancreatic and small-cell lung cancer.


Previous articleMicroglia’s Role in Neurodegenerative Disease Receives Further Scientific Support
Next articleOBI Acquires Threshold’s Anticancer Prodrug for AKR1C3-Expressing Cancers